A critical factor in edible plant-derived vaccine development is adequate expression of the exogenous antigens in transgenic plants. We synthesized a codon-optimized gene (sVP6) encoding the VP6 protein of human group A rotavirus and inserted it into the alfalfa genome using agrobacterium-mediated transformation. As much as 0.28% of the total soluble protein of the pBsVP6-transgenic alfalfa was sVP6. Female BALB/c mice were gavaged weekly with 10 mg of transgenic alfalfa extract containing 24 Ag of sVP6 protein and 10 Ag of CpG-rich oligodeoxynucleotides as mucosal adjuvant. Immunized mice developed high titers of anti-VP6 serum IgG and mucosal IgA. Offspring of immunized dams developed less severe diarrhea after challenge with simian rotavirus SA-11, indicating that antibodies generated in the dams provided passive heterotypic protection to the pups. These results suggest that oral immunization with pBsVP6-transgenic alfalfa provides a potential means of protecting children and young animals from severe acute rotavirus-induced diarrhea. D
Introduction
Plants have considerable potential for the production of biopharmaceutical proteins because they are easily transformed and provide an inexpensive source of protein. The production of a subunit vaccine in transgenic plants was first reported by Mason et al. (1992) , who integrated a DNA fragment encoding the hepatitis B surface antigen (HBsAg) into the genome of tobacco plants using agrobacteriummediated transformation. In this system, the expressed HBsAg retains the capacity to self-assemble into virus-like particles, which is a much more immunogenic form of the antigen than the peptide alone (Mason et al., 1992) . Since then, several groups have used plants to express a variety of bacterial and viral antigens. Escherichia coli heat labile B subunit (LTB), cholera toxin B subunit (CTB), foot and mouth disease virus (FMDV) VP1 protein, Norwalk virus capsid protein, respiratory syncytial virus F protein, and measles virus hemagglutinin have been successfully expressed in plants and delivered orally to animals or humans to determine their respective immunogenicities (Arakawa et al., 1998; Huang et al., 2001; Mason et al., 1998; Sandhu et al., 2000; Tacket, 2000; Wigdorovitz et al., 1999) .
Tobacco and potato plants were employed as test systems in early plant-derived vaccine research because of the ease of transformation and regeneration in these models. However, tobacco leaves are inedible, making protein extraction a necessary step prior to the administration of the product as an oral vaccine. Potatoes are not normally eaten raw, but cooking would denature the transgenic proteins and reduce the immunogenicity. Other candidate host plants such as tomato, banana, corn, lettuce, and alfalfa have been used for plant-derived vaccine production (Streatfield et al., 2003; Tacket and Mason, 1999; Wigdorovitz et al., 1999) . Alfalfa (Medicago sativa L.) is a perennial crop that continues to produce for up to 5 years after establishment. The plant has a strong regenerative capacity and can be propagated by stem cuttings to produce large clonal populations within a limited time period. The low levels of secondary metabolites and high protein content in the leaves of alfalfa make it a good bioreactor for the production of recombinant proteins (Erickson et al., 2002) . Dus Santos et al. (2002) reported a simple method to obtain transgenic alfalfa expressing high levels of foreign epitopes (VP135-160) from FMDV. The FMDV epitope expressed in plants was highly immunogenic in mice, which developed a strong anti-FMDV antibody after immunization.
Rotaviruses are the most important causes of viral gastroenteritis in young children and animals worldwide. Most children are infected with rotavirus at least once before they are 3 years old, and approximately 6% of deaths among children in developing countries are attributable to rotavirus infection (Dodet et al., 1997) . Thus, there is an urgent need to develop safe and effective vaccines against rotavirus infection. The nucleocapsids of the group A rotaviruses are composed of three concentric layers of proteins enclosing 11 segments of double-stranded RNA. The outer capsid layer is composed of two proteins, VP7 and VP4, which are the only targets of neutralizing antibodies and define the G and P serotypes, respectively, of viral isolates (Ramig, 1997) . The innermost capsid layer consists of protein VP2, whereas the intermediate layer is formed by protein VP6, which constitutes approximately 51% of the virion by weight. Antibodies against VP6 are highly cross-reactive among all group A rotaviruses; therefore, VP6-based vaccines could potentially provide heterotypic protection (Prasad and Chiu, 1994) . Although anti-VP6 antibodies do not exhibit virus neutralizing activity, anti-VP6 secretory IgA has a critical role in protective immunity against rotavirus infection (Burns et al., 1996) . Anti-VP6 IgA confers protection in vivo by inhibiting viral transcription at the start of the intracellular phase of the viral replication cycle (Feng et al., 2002) . In addition, immunization with VP6 may prime the immune system for enhanced production of neutralizing antibodies against the external proteins (VP7 and VP4) upon challenge with homotypic or heterotypic viruses (Esquivel et al., 2000) .
Based on these and other results, several candidate VP6-based vaccines have been developed. Immunization with VP6 DNA or virus-like particles composed of VP2 and VP6 efficiently protected mice from rotavirus infection (Conner et al., 1996; Yang et al., 2001) . The VP6 genes of bovine or murine rotaviruses were expressed in transgenic potatoes after Agrobacterium tumefaciens-mediated transformation (Matsumura et al., 2002; Yu and Langridge, 2003) . However, the amount of VP6 protein produced in transgenic potato tubers is low, being limited to approximately 0.002% to 0.1% of the total soluble protein (Matsumura et al., 2002; Yu and Langridge, 2003) . The VP6 gene was also expressed in Nicotiana benthamiana from potato virus X vectors, and the expressed protein was shown to self-assemble into viruslike particles (O'Brien et al., 2000) . Although some of these oral vaccine candidates elicited specific anti-VP6 serum IgG and mucosal IgA antibodies (Matsumura et al., 2002; Yu and Langridge, 2003; García-Díaz et al., 2004) , few data on challenge experiments are available. However, the low levels of antigenic proteins in the plant materials suggest that increased VP6 expression in transgenic plants will be a key factor in oral vaccine development.
Here, we report that M. sativa transformed with the pBsVP6 vector expressed a high level of human group A rotavirus sVP6 protein. Immunization with extracts of the transgenic alfalfa leaves elicited an efficient immune response in mice that provided passive protection against infection with simian rotavirus SA-11 in neonatal mice born to immunized dams.
Results

A codon-optimized sVP6 gene has been synthesized
To optimize the coding sequence of the VP6 gene from human group A rotavirus (GenBank accession no.AF260931) for expression in alfalfa, the 1194-nucleotide coding sequence was modified to yield a new sequence, sVP6, in which a number of codons were altered to match the codon usage preferences of dicots. The GC content of the gene was increased from 35% to 44%, which closely approximated that of highly expressed dicot genes. In addition, four ATTTA motifs, six potential polyadenylation signal sequences, and one potential termination site for RNA polymerase II were eliminated to permit transcription of intact, mature, and translatable mRNA. The amino acid sequence encoded by the modified sVP6 was identical to that of the original VP6 gene to ensure retention of the antigenicity of the transgenically expressed protein. The nucleotide sequence of the sVP6 gene (GenBank accession no. AY803761) was 87.94% homologous to the original VP6 gene.
The structure of the sVP6 protein is similar to the native VP6 SDS-polyacrylamide gel electrophoresis (PAGE) analysis demonstrated that glutathione S-transferase (GST) fusion proteins of sVP6 and VP6 (GST-sVP6 and GST-VP6) expressed in E. coli BL21 were of equal size (65 kDa). The sVP6 protein purified by GST affinity chromatography thrombin, and fast protein liquid chromatography (FPLC) had a relative molecular weight of 42 kDa under denaturing conditions (treated samples for 5 min at 100 -C, sample buffer containing h-mercaptoethanol). Both sVP6 and native VP6 proteins were monomer (42 kDa) under denaturing condition, while existed as trimers (¨130 kDa) under nondenaturing conditions (treated samples for 30 min at 37 -C, sample buffer without h-mercaptoethanol). Western blot analysis further confirmed that the sVP6 protein and its trimers bound rabbit polyclonal anti-rotavirus VP6 antibodies (Fig. 1) . These results indicated that the structure of the sVP6 protein is similar to that of native VP6.
Construction of the transformation vector pBsVP6
The transformation vector pBsVP6 contains the cauliflower mosaic virus (CaMV) 35S promoter with dual enhancers to drive transcription of the sVP6 gene and the nopaline synthase (nos) terminator to stop transcription. The 5V-untranslated region of the tobacco etch virus (TEV) serves as a translation enhancer, and a Kozak sequence is present to optimize translation. A sequence encoding the endoplasmic reticulum retention signal SEKDEL was fused to the 3V end of sVP6 gene to ensure intracellular compartmentalization of the fusion protein. pBsVP6 also contains the kanamycin resistance marker (NPT II) which permits the selection of transformed plants (Fig. 2) .
Genetic analysis of transformed alfalfa
Agrobacterium tumefaciens LBA4404 was transformed with pBsVP6 and used for alfalfa transformation. Ten to 12 weeks after transformation, 78 kanamycin-resistant plants were obtained. To confirm that the sVP6 gene was stably integrated into the chromosomal DNA of the transformed alfalfa, genomic DNA and total RNA were extracted from young leaves of transgenic plants and analyzed by Southern blotting and RT-PCR, respectively. Genomic DNA samples and recombinant pBsVP6 plasmid were digested with SacI and HindIII restriction endonucleases outside the target gene. Southern blot showed that the profiles of digested products (band size) are different among transgenic plants, and between SacI and HindIII double-digested pBsVP6 and HindIII-excised pBsVP6 plasmid; whereas no bands were detected in the untransformed plants. These data confirmed the integration of sVP6 gene into plant genome, but not the contamination of plant with A. tumefaciens (Fig. 3A) . Transcription of the Fig. 1 . Detection of recombined sVP6 protein by Western blotting with rabbit anti-VP6 antibodies. Samples were treated for 5 min at 100 -C under denaturing conditions (lanes 2 and 4) or for 30 min at 37 -C under nondenaturing conditions (lanes 1 and 3) , then subjected to SDS-PAGE and blotted onto a nitrocellulose membrane. After blocking, the membrane was reacted with rabbit anti-VP6 polyclonal antibody, then with alkaline phosphatase-conjugated goat anti-rabbit IgG. Finally, the membrane was developed by NBT/BCIP. Lanes 1 and 2: purified sVP6 protein expressed in E. coli; lanes 3 and 4: purified native VP6 protein (control) expressed in E. coli; M: protein molecular weight markers. Fig. 2 . Construction of the plant transformation vector pBsVP6 for the expression of the human rotavirus sVP6 gene in alfalfa. The DNA region inserted into the alfalfa genome contained two cassettes: the NPT II cassette, which confers kanamycin resistance to plants, and the human rotavirus sVP6 expression cassette. The 35S promoter with dual enhancers from cauliflower mosaic virus was used to drive transcription, and the nopaline synthase terminator was used to stop transcription. The 5V-untranslated region of the tobacco etch virus (TEV) served as a translation enhancer, and a Kozak sequence was included to optimize translation. The SEKDEL retention signal was fused to the 3V end of the sVP6 gene. sVP6 gene in the transgenic plants was detected by the generation of a single 1.2-kb product in tested lines after RT-PCR, whereas no specific products were detected in the wild-type plants (Fig. 3B ). These results demonstrated that the sVP6 gene was integrated into the nuclear genome and expressed in transgenic alfalfa.
Expression of sVP6 protein in transgenic alfalfa
Total soluble protein (TSP) was extracted from transformed alfalfa leaves to examine the expression of sVP6 protein. Western blotting showed that recombinant sVP6 protein (¨42 kDa) was produced in the transformed plants and in recombined E. coli, whereas no sVP6 protein was detected in the untransformed plants (Fig. 4A ). The quantification of sVP6 by sandwich ELISA showed that 0.06 to 0.28% of the TSP was sVP6; 18 transformed plants expressed sVP6 protein in the range of 7.08 to 33.04 Ag/g of fresh leaf weight (Fig. 4B ). Western blotting using rabbit anti-rotavirus VP6 serum further confirmed that sVP6 protein (42 kDa) was stably expressed in the first transgenic (T1) generation of alfalfa as in T0 generations (Fig. 4C) . These results suggested that alfalfa is a promising system for vaccine production. 
Antibody responses in mice after administration of TSP from pBsVP6-transgenic alfalfa leaves
To test the immunogenicity of sVP6 from transgenic plant, six of the transgenic plants ( Fig. 4B lanes 4 , 5, 8, 14, 15 and 16 ) that expressed high levels of sVP6 protein were grown in a greenhouse and propagated by stem cuttings. Mice were gavaged on days 0, 7, 14, and 21 with 10 Ag of oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs as a mucosal adjuvant and with 10 mg of TSP extracted from the transgenic or control untransformed plants, or with 24 Ag of recombinant sVP6 purified from E. coli. As shown in Fig. 5A , mice gavaged with transgenic TSP containing 24 Ag of sVP6 protein developed specific anti-VP6 IgG with ELISA titers between 1:6,000 and 1:9,600. These titers were somewhat higher than those elicited in mice immunized with sVP6 from E. coli, which ranged from 1:4,800 to 1:7,200. The ELISA titers of mucosal IgA in the saliva, feces, and homogenized small intestines of mice immunized with transgenic alfalfa extract were also determined. The titers of anti-VP6 IgA found in the saliva (Fig. 5C ) and feces ( Fig. 5D) were lower than those found in the small intestine homogenate (Fig. 5B) , which ranged from 1:320 to 1:640. Mice gavaged with wildtype alfalfa extract did not produce anti-VP6 antibodies.
The specificity of the anti-sVP6 antibody produced by the immunized mice was further confirmed by Western blotting using both purified sVP6 and rotavirus particles. The sera from the mice immunized with pBsVP6-transformed plant extract specifically recognized both sVP6 protein and native VP6 from rotavirus particles, whereas the sera from animals immunized with untransformed alfalfa did not show reactivity to sVP6 or native rotavirus particles (Fig. 6 ).
Rotavirus challenge experiments
As mice are susceptible to rotavirus-induced diarrhea only during the first 15 days of life, 5-day-old pups born to immunized dams were challenged with 20DD 50 simian rotavirus SA-11 to evaluate the passive protection against rotavirus-induced diarrhea. The first group was consisted of 30 pups bred by 10 wild-type-alfalfa -immunized female mice, the second group was consisted of 32 pups bred by 10 transgenic-alfalfa-immunized female mice, and the third group was consisted of 24 pups bred by 10 recombinantsVP6-protein-immunized female mice. After challenge, the anus of each pup was checked three times per day. The anus of diarrheic mice was reddish and adhered with plenty of feces, and the diarrheic symptomatic difference between normal and diarrheic mice was obvious. Diarrhea symptom of infected mice had been continuously observed for 10 days, and the intensity of diarrhea were determined according to the color of anus and the amount of adhered feces.
The proportion of pups with diarrhea symptoms, the duration of diarrhea and the intensity of diarrhea were significantly reduced in the offspring of mice immunized with the transgenic alfalfa. Complete resolution of diarrhea symptoms occurred 5 days after virus challenge in pups from transgenic-alfalfa-immunized female mice (Fig. 7) . These results suggested that the anti-VP6 antibodies generated in orally immunized female mice were passively transferred to the pups and provided heterotypic protection, indicating that a plant-derived sVP6-based oral vaccine could efficiently protect young animals and children from severe acute diarrhea caused by human group A rotaviruses.
Discussion
Rotaviruses are the leading cause of severe gastroenteritis and dehydrating diarrhea in young children and animals worldwide. Many newborn animals are susceptible to rotavirus-induced diarrhea only during the first weeks of life, making it difficult to actively immunize the animals before exposure to the pathogen. As female mice are able to passively transfer antibodies to their pups, we challenged pups born to immunized dams with rotaviruses to study the protection provided by immunization with transgenic alfalfa expressing VP6. The rotavirus outer capsid proteins VP4 and VP7 have long been considered the targets for protective immunity in vaccine development, as VP4 and VP7 determine the virus serotype and mediate neutralization. However, several studies have suggested that the levels of the neutralizing antibody response do not always correlate with protection (Ward et al., 1992a (Ward et al., , 1992b . Non-neutralizing IgA monoclonal antibodies directed against the intermediate capsid protein VP6 can mediate immunity against rotaviruses in vivo (Franco and Greenberg, 1999; Feng et al., 2002) . The induction of efficient protection against rotavirus correlated with the level of Fig. 7 . Protection against rotavirus infection in passively immunized murine pups. On the fifth day post parturition, mouse pups were challenged with 20 DD 50 of simian rotavirus SA-11. The diarrhea symptoms and intensity of diarrhea were observed at least 10 days after challenge. The percentage of pups with diarrhea symptoms was calculated. The number of pups that developed diarrhea comparison to the total number of pups in each group is indicated on the top of each column. Group 1: 30 pups bred by 10 untransgenic-alfalfa-immunized female mice. Group 2: 32 pups bred by 10 transgenic-alfalfa-immunized female mice. Group 3: 24 pups bred by 10 recombinant-sVP6-protein-immunized female mice. Fig. 6 . The specificity of the antibodies from mice immunized with leaf extracts from pBsVP6-transformed alfalfa as detected by Western blotting. Several pools of sera from mice immunized with pBsVP6-transformed plants (lanes 1 -6) or with wild-type plants (lanes 7 -8) were analyzed using purified sVP6 protein (lanes 2, 4, 6, and 8) and rotavirus particles (lanes 1, 3, 5, and 7) as antigens. M, protein molecular weight markers.
intestinal IgA (VP6 is a notable exception) but not with the level of rotavirus-specific serum IgG (Franco and Greenberg, 1999) . The intestinal IgA response in T cell-deficient mice was roughly one-tenth that of immunocompetent mice and was directed exclusively against VP6 (Franco and Greenberg, 1999) . Colostral antibodies produced in female mice immunized with rotavirus VP4 or VP7 have been reported to confer passive protection to their newborn offspring (Kim et al., 2002; Wigdorovitz et al., 2004) . No successful passive immunization using VP6-based vaccines has previously been reported. In this study, the severity and duration of diarrhea induced by challenge with simian rotavirus SA-11 were reduced significantly in passively immunized pups, indicating that anti-VP6 antibodies generated in orally immunized female mice can be transferred to their offspring.
The mucosal surfaces of the gastrointestinal, genitourinary, and respiratory tracts are the primary entry sites of most pathogens. The induction of effective mucosal immunity could greatly reduce the rates of infection and morbidity. Thus, mucosal immunization, especially by the oral route, has recently attracted much interest. The expression of viral and bacterial antigens in plants has opened up a new avenue for oral vaccine development. Compared with the traditional routes of immunization, the delivery of antigens produced in transgenic plants by the oral route can potentially elicit production of effective levels of local secretory IgA, which is the hallmark of mucosal immunity. IgA is thought to protect the host against pathogens that infect mucosal surfaces and those that cause systemic disease after entry via a mucosal surface (Lamm, 1997) . Oral vaccines have been proposed as particularly suited for use in developing countries because of the ease of production, handling, and administration, without risk of needle-stick injury or cross-contamination. Rotavirus-specific IgA production has been demonstrated in the Peyer's patches and cells from mesenteric lymph nodes cultured in vitro after intranasal and oral administration of a VP6 DNA vaccine (García-Díaz et al., 2004) . It has been previously suggested that the expression of antigens in plants could provide ''bio-encapsulation'' for the antigens and protect them from degradation in the digestive tract until the plant cells are degraded near the Peyer's patches, which function as effector sites for the initiation of mucosal immunity (Kong et al., 2001) . It is also possible that proteins or secondary metabolites (e.g. polyphenolics) from plant cells may associate with HBsAg and account for its protection in the gastrointestinal tract (Kong et al., 2001) . Basing on our data (Fig. 5) , we propose the possible mechanism of uptake of VP6 protein expressed in transgenic alfalfa into intestine is similar to that of HBsAg as described above. Bioencapsulation of VP6 antigens made in transgenic plants may result in the induction of significant mucosal immune responses that are otherwise difficult to achieve.
The previously reported levels of antigenic proteins expressed in transgenic plants are as low as 0.01% and do not exceed 0.40% of the total soluble protein. Although the recombinant target proteins expressed in chloroplast-transformed tobacco and tomato plants can be up to 46% of total soluble protein, this level of expression is difficult to attain in other crops (Sala et al., 2003) . Potato plants transformed with a codon-optimized sLTB gene accumulated 5-to 40-fold more LTB in the leaves than did lines transformed with the unmodified LTB gene (Mason et al., 1998) . The eBRV4 peptide, which contains at least one neutralizing epitope of the VP4 protein of bovine rotavirus (BRV), was efficiently expressed in transgenic alfalfa as a fusion protein with the stable reporter enzyme h-glucuronidase (h-GUS); the maximum expression level of recombinant eBRV4-hGUS protein in transgenic lines was 0.9 mg/g TSP. The eBRV4 epitope expressed in plants was effective in inducing an anti-rotavirus antibody in adult female mice, when administered either intraperitoneally or orally. The suckling mice born from immunized female mice were protected against oral challenge with virulent rotavirus. (Wigdorovitz et al., 2004) . Here, we showed that the expression of sVP6 protein in transformed alfalfa leaves was highly increased by using optimized codons, as well as the 35S CaMV promoter, a Kozak sequence, the TEV leader sequence, and the SEKDEL retention signal. As shown in Fig. 4B , the expressed VP6 protein in the leaves of transgenic alfalfa reached 33.04 Ag/g of fresh leaf weight, or 0.28% of TSP, and successfully elicited the production of serum IgG and mucosal IgA antibodies in immunized mice.
Another limitation of the plant-based oral vaccines that have been tested in clinical trials is the lack of a safe and effective mucosal adjuvant for use in humans. The most powerful mucosal adjuvants described to date are cholera toxin (CT) and the closely related heat-labile enterotoxin (LT) of E. coli; however, toxicity prevents their use in humans. To avoid toxicity, the use of CT and LT mutants or B subunits has been explored, but their activities as mucosal adjuvants have proven to be much lower than those of the respective holotoxins (Holmgren et al., 2003) . A novel mucosal adjuvant is composed of ODN containing immunostimulatory CpG motifs. CpG ODN is an effective oral adjuvant that can promote or enhance systemic and mucosal immune responses to both weak (HBsAg) and strong (tetanus toxoid) protein antigens (McCluskie et al., 2001 ). The intranasal administration of CpG ODN together with purified protein antigens promotes a mucosal Th2 response with the formation of IgA and a systemic Th1 response. Some reports have shown that the intranasal delivery of CpG ODN induced responses stronger than those induced by cholera toxin B subunit and equivalent to those induced by CT (McCluskie et al., 2000) . In this study, CpG ODN was used for the first time as a mucosal adjuvant for an oral vaccine derived from pBsVP6-transgenic alfalfa. The strong immune responses elicited in immunized mice, including high titers of anti-VP6 IgG and IgA, suggest that CpG ODN is a safe and efficient mucosal adjuvant for oral vaccines.
Further testing will be required to determine whether it is suitable for large animal models and humans.
In conclusion, sVP6 protein was expressed at high levels in transgenic alfalfa and successfully induced specific serum IgG and mucosal IgA antibodies in mice. Passively immunized mouse pups exhibited reduced diarrheal symptoms compared with controls following challenge with simian rotavirus SA-11. These results demonstrate that pBsVP6-transgenic alfalfa is a candidate oral vaccine for the protection of children and young animals against rotavirus infection.
Materials and methods
Modification of the coding sequence of the VP6 gene
To optimize the coding sequence for expression in alfalfa, the 1194-nucleotide coding sequence of VP6 from the human rotavirus group A strain 97'B53 (GenBank accession no. AF260931) was analyzed, and its codon usage was compared with the previously reported codon usage of dicotyledonous plant genes (Perlak et al., 1991) . A number of codons in the VP6 coding sequence were then modified to yield a sequence consistent with dicot codon usage. We also modified a number of sequences that can potentially destabilize mRNA, including potential polyadenylation signal sequences (AATAAA, AATGAA, AATAAT, AATATT, AATTAA, AATAAG, AACCAA, GATAAA; located at nucleotide positions 46 -51, 257 -262, 378 -383, 509 -514, 769 -774, and 1015 -1020) , mRNA destabilizing motifs (ATTTA; located at nucleotide positions 99 -103, 158 -162, 369 -373, and 693 -697) , potential termination signals for RNA polymerase II (AGTNNAA; located at nucleotide positions 780-786), and plant RNA splice site consensus sequences. The AT content of the modified gene was 56%, which accords with the AT content in highly expressed dicot proteins. The modified gene (sVP6) encoded an amino acid sequence identical to that encoded by the original VP6 gene.
To optimize the expression of the protein in transgenic plants, a plant translation initiation sequence (AAC-CATGGCT) was added at the 5V end of the coding region. A DNA sequence encoding the peptide SEKDEL (TCT GAG AAA GAT GAG CTA) was ligated to the 3V end of the modified gene to ensure retention of the expressed VP6 protein in the endoplasmic reticulum of the plant cell. The modified synthetic gene was constructed into the pUC19 vector, forming the recombinant vector pUsVP6 (Shanghai Sangon Company, Shanghai, China).
Analysis of sVP6 proteins expressed in E. coli
To examine expression in prokaryotic cells, the sVP6 and VP6 genes were inserted into pGEX4T-1 at the BamHI and XhoI sites, respectively, and the plasmids were transformed into E. coli BL21. The expressed sVP6 and VP6 proteins were purified by GST affinity chromatography, thrombin, and FPLC. The purified VP6 proteins were used to immunize rabbits for the production of polyclonal anti-VP6 serum. Samples of the purified sVP6 and VP6 proteins were incubated at 100 -C for 5 min in Laemmli loading buffer (Laemmli, 1970) and analyzed by SDS-PAGE using a 10% resolving gel and a 4% stacking gel. The nondenatured sVP6 and VP6 proteins were examined by incubating the samples at 37 -C for 30 min without h-mercaptoethanol before analysis by SDS-PAGE (O'Brien et al., 2000) . The separated proteins were transferred onto nitrocellulose membranes for Western blotting using an Electro-transfer unit (Bio-Rad, Hercules, CA, USA). After blocking with phosphate-buffered saline (PBS) containing 0.05% Tween-20 (PBST) and 5% skim milk for 3 h at 37 -C or overnight at 4 -C, the membranes were reacted with rabbit antirotavirus VP6 antibody (1:1,000), followed by alkaline phosphatase-labeled goat anti-rabbit IgG (1:5,000) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After washing, the reaction was developed by the addition of nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/ BCIP) substrate.
Construction of the plant expression vector
The sVP6 fragment including the 3V SEKDEL sequence (1.2 kb) was cleaved from pUsVP6 using NcoI and SacI and was ligated into the vector pRTL2 to yield pRsVP6, placing the sVP6 gene downstream of the CaMV 35S promoter with double enhancers to drive expression and the TEV 5V untranslated region (5V-UTR) to mediate the enhancement of translation initiation. The DNA fragment containing the 35S promoter, the 5V-UTR, and the sVP6-SEKDEL sequence was inserted into the binary plant vector pBI121 digested with HindIII and SacI to produce the recombinant expression vector pBsVP6.
Plant transformation and regeneration
pBsVP6 was transformed into A. tumefaciens strain LBA4404 by the freeze -thaw method, and the integrity of the plasmids from LBA4404 was verified by PCR amplification, restriction digestion, and comparison with pBsVP6 from the parent E. coli DH5a cells. Alfalfa plants were transformed using leaf disc co-cultivation with some modifications (Desgagnés et al., 1995) . The alfalfa seeds were grown in half-strength MS medium at 23 -C with a 16 h light and 8 h dark photoperiod. After 7 days, the cotyledons and hypocotyls were sliced into pieces approximately 3 cm in length and soaked in the A. tumefaciens inoculum supplemented with 50 AM acetosyringone (Aldrich, USA) for 15 to 30 min at room temperature. After 4 days on callus medium without antibiotics, the plant discs were thoroughly washed with sterile water, layered on selection medium (SH medium supplemented with 2 Ag/ml of 2,4-dichlorophenoxyacetic acid, 0.025 Ag /ml of kinetin, 250 Ag/ml of carbenicillin, and 25 Ag/ml of kanamycin), and incubated for 2 to 3 weeks. The resistant calluses were transferred to differentiation medium (SH medium supplemented with 0.4 Ag/ml of kinetin, 200 Ag/ml of carbenicillin, and 25 Ag/ml of kanamycin) for embryonic development and maturation. The plants were regenerated on half-strength MS medium without hormones. Plants with well-defined shoots and roots were transferred to vermiculite and subsequently to soil.
Southern blotting and RT-PCR analysis of transformed alfalfa
Genomic DNA was isolated from young leaves of transformed and wild-type alfalfa plants using a plant DNA extraction kit (TaKaRa Bio Inc., Japan), and aliquots of each were digested with two restriction endonucleases (SacI and HindIII) outside the sVP6 gene to show insertion of gene into the plant genome. The pBsVP6 plasmid has only one recognition site for each enzyme, permitting the estimation of the complexity of the transgene copy integration. The digested DNA samples were electrophoresed on 0.8% agarose gels and transferred onto Hybond N + nylon membranes (Amersham Biosciences, USA.) for hybridization. The probe was prepared from the 1.2-kb sVP6 gene fragment by incorporation of a-32 P dCTP using a random-primer DNA labeling kit (Promega, Madison, WI, USA). Standard protocols were used for Southern blot analysis.
Total RNA was extracted from the leaves of transformed and wild-type alfalfa plants using a plant RNA extraction kit (TaKaRa). The expressed sVP6 mRNA was amplified by RT-PCR from total RNA using an RT-PCR kit (TaKaRa) with primers P1 (5V-ATG GAG GTT CTG TAC TCA TTG TC-3V) and P2 (5V-AGA CTT GAT CAA CAT GCT TCT-3V). The PCR products were separated by electrophoresis on a 0.8% agarose gel and visualized under UV light after staining with ethidium bromide.
Total soluble protein extraction and Western blot analysis
Alfalfa leaves were homogenized in liquid nitrogen with a mortar and a pestle by the addition of an extraction buffer containing 10 mM sodium phosphate buffer (pH 7.2, 105 mM NaCl, 0.05% Tween, 40 mM acid ascorbate, 20 mM EDTA, and 1 mM PMSF). The total soluble protein was precipitated with (NH 4 ) 2 SO 4 between 30% and 60% saturation. The TSP was resuspended in PBS and dialyzed before oral immunization or immunoassay.
For Western blot analysis, TSP samples were separated by SDS-PAGE and transferred onto nitrocellulose membranes using an Electro-transfer unit (Bio-Rad). The membranes were sequentially incubated with rabbit polyclonal anti-VP6 antibody (1:1,000) and alkaline phosphatase-conjugated goat anti-rabbit IgG (1:5,000; Santa Cruz Biotechnology), and the color reaction was developed as described above for the proteins expressed in E. coli. To determine the stability of the sVP6 gene in the transgenic alfalfa, Western blotting was also used to analyze proteins extracted from the T1 generation of the original transformed lines.
ELISA quantification of sVP6 protein levels in transgenic plants
A 96-well ELISA plate was coated with mouse anti-VP6 serum in carbonate buffer (pH 9.6) overnight at 4 -C. The plate was washed three times with PBST and blocked with 3% BSA in PBST for 2 h at 37 -C. Aliquots of TSP extracts from transgenic plants and samples of known amounts of purified sVP6 protein (42 kDa) from recombinant E. coli comprising a standard curve were added to the wells, and the plate was incubated for 1 h at 37 -C. After three washes, the plate was incubated with rabbit anti-VP6 serum (1:1,000) for 1 h at 37 -C, followed by additional washes and incubation with horseradish peroxidase-labeled goat anti-rabbit IgG (1:5,000; Santa Cruz) for 1 h at 37 -C. The reaction was developed by the addition of o-phenylenediamine-H 2 O 2 in citrate buffer (pH 5.0). The absorbance at 492 nm was measured using a microplate reader. The expression of the sVP6 protein in the transgenic plants was quantified by comparison with the standard curve.
Oral immunization of mice and antibody assay
Thirty female BALB/c mice (6 -8 weeks old; Experimental Animal Center, Peking Union Medical College, Beijing, China) were divided into three groups and immunized orally at weekly intervals for 4 weeks (days 0, 7, 14, and 21) with the protein samples. CpG ODN 1826 (10 Ag) was included as a mucosal adjuvant because it is a strong B cell mitogen and a safe adjuvant for mucosal immunization (McCluskie et al., 2001) . The sequence of CpG ODN 1826 is TCC ATG ACG TTC CTG ACG TT, and it has a phosphorothioate backbone.
The ten negative control mice in group 1 were gavaged with 10 mg of TSP from untransformed alfalfa leaves and CpG adjuvant. The ten mice in group 2 were gavaged with 10 mg of TSP from transgenic alfalfa, which contained 24 Ag of sVP6 protein from transgenic alfalfa, and CpG adjuvant. The ten positive control mice in group 3 received 24 Ag of purified sVP6 from recombinant E. coli and CpG adjuvant. Saliva and feces samples (homogenized in 0.01 M PBS) were collected weekly from each animal for analysis of anti-VP6 IgA. On day 36, serum samples were collected and tested for IgG titers. On day 60, four mice in each group were sacrificed, and the small intestines were collected and homogenized in 0.01 M PBS for analysis of mucosal IgA.
The levels of anti-VP6 IgG and IgA were assayed by ELISA using recombinant sVP6 protein as the antigen. A 96-well ELISA plate was coated with purified sVP6 protein in carbonate buffer (pH 9.6) overnight at 4 -C. The plate was washed three times with PBST and blocked with 3% BSA in PBST for 2 h at 37 -C. Blocking buffer were discarded and diluted mouse serum (or saliva, homogenized feces, homogenized small intestine) samples were added to the wells, and the plate was incubated for 1 h at 37 -C. After three washes, peroxidase-conjugated goat anti-mouse IgG (Santa Cruz) or peroxidase-conjugated goat anti-mouse IgA (Zymed, South San Francisco, CA) was used as the second antibody to detect anti-VP6 IgG or IgA, respectively. The reaction was developed by the addition of o-phenylenediamine-H 2 O 2 in citrate buffer (pH 5.0). Color development was stopped by addition of an equal volume of 6 M H 2 SO 4. The antibody titers were expressed as the reciprocal of the highest serum dilution yielding an OD 492 that was at least two-fold the mean OD 492 for serum samples from the negative controls.
SDS-PAGE and Western blot analysis were conducted to confirm the specificity of the antibodies. Inactivated purified rotavirus particles and purified sVP6 protein samples were incubated at 100 -C for 5 min in Laemmli loading buffer before loading on SDS-PAGE gels. The Western blot analysis was performed as described above for the detection of the sVP6 protein from E. coli, using the sera from the immunized mice (1:50) as sample, and alkaline phosphatase-conjugated goat anti-mouse IgG as the second antibody (Santa Cruz Biotechnology; Wigdorovitz et al., 2004) .
Challenge experiments
The remaining immunized female mice were mated with normal males on day 61 after the first immunization. Mouse pups were born after a 19-to 20-day gestation period. On the fifth day post parturition, pups were challenged using the method of Yu and Langridge (2001) . Each pup was challenged with 20 DD 50 of simian rotavirus strain SA-11. The DD 50 was the empirically determined viral dose that induced diarrhea in 50% of native newborn mice. After SA-11 virus challenge, the anus of each pup was checked three times per day. The infected mice without watery feces during the three-time check were classified as non-diarrheic mice, otherwise classified as diarrheic mice. The intensity of diarrhea was determined according to the color of anus and the amount of adhered feces. The proportion of pups showing diarrhea symptoms and the intensity of the diarrhea symptoms were observed for at least 10 days after challenge.
